Table 2.
Results for clinical manifestations of included studies
| Intervention | Subjects | Baseline outcomes | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||
| Author | Background treatment | Study arms | Duration (wk) | No. | Male (%) | Age (y) | Disease duration (y) | BMI (kg/m2) | Weight (kg) | HbA1c (%) |
| Hollander 2011 | MET ± OADs | Determir + sitagliptin vs. sitagliptin | 26 | 217 | 54.4 | 57 | 9.8 | 31.9 | 90.7 | 8.5 |
| Barnett 2012 | Basal or premixed insulin ± MET | Saxagliptin vs. placebo | 24 | 455 | 41 | 57.3 | 12 | 32.2 | 87.0 | 8.7 |
| Hong 2012 | Basal or mixed insulin ± OADs | Sitagliptin vs. insulin | 24 | 124 | 52.4 | 59.2 | 15.9 | 25.6 | 67.4 | 9.2 |
| Vilsbol 2010 | Basal or premixed insulin ± MET | Sitagliptin vs. placebo | 24 | 641 | 50.9 | 57.8 | 12.5 | 31 | 86.9 | 8.7 |
| Yki-Jarvinen 2013 | Basal insulin ± MET ± pioglitazone | Linagliptin vs. placebo | 52 | 1261 | 52.2 | 60 | Not informed | 31 | Not informed | 8.3 |
| Fonseca 2007 | Basal or mixed insulin | Vildagliptin vs. placebo | 24 | 296 | 51.4 | 59.3 | 14.7 | 33.1 | 94.8 | 8.4 |
| Rosenstock 2009 | Basal insulin ± MET | Alogliptin vs. placebo | 26 | 390 | 41.3 | 55.4 | 12.6 | 32.5 | 88.5 | 9.3 |